Dofetilide

Dofetilide, sold as Tikosyn, is a medicine taken by mouth that the US label describes as an antiarrhythmic drug with Vaughan Williams Class III activity; it blocks a potassium current in the heart. The label read lists two uses: the maintenance of normal sinus rhythm (delay in the time to recurrence of atrial fibrillation or flutter) in patients with atrial fibrillation or flutter of more than a week's duration who have been converted to normal sinus rhythm, and the conversion of atrial fibrillation and flutter to normal sinus rhythm. It says the medicine has not been shown to be effective when the atrial fibrillation is paroxysmal. The label carries a boxed warning about induced arrhythmia.

Also called Tikosyn

  • Drug
  • In this atlas

Overview

Technical summary

RxNorm ingredient 49247 (dofetilide, no salt); UNII R4Z9X1N2ND (exact). MeSH has no descriptor for dofetilide (the exact-label descriptor lookup returned an empty list); the term dofetilide exists (T205355) but is not a descriptor, so no MeSH code was added. RxClass lists the FDA established pharmacologic class Antiarrhythmic, and the openFDA record of the label carries the same class (Antiarrhythmic [EPC]). The label read is the Pfizer Laboratories Div Pfizer Inc label for Tikosyn capsules, application NDA020931, effective 2026-04-21 in openFDA. Drugs@FDA also lists a generic product (ANDA210740) whose brand name is a misspelling of dofetilide; generic labels were not read. This page records label indications, the class, the mechanism sentence and the boxed warning only: no trial result and no dose is given.

About this drug

Level
Substance
Mechanism
The label says dofetilide shows Vaughan Williams Class III antiarrhythmic activity by blocking the cardiac ion channel that carries the rapid component of the delayed rectifier potassium current.

Claims and evidence

Context Patients starting or restarting Tikosyn, as described in a US label boxed warning

Recipient
Recipient not specified
Population
Patients who are started or restarted on the medicine, as the boxed warning describes them. The passages read give no age range.
Care setting
Prescription medicine, as described in the US label
Geography
United States (label of the US Food and Drug Administration)
Life stage
Not stated in the label passages read
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
Included
  • Patients initiated or re-initiated on Tikosyn
Excluded
None stated
  • Safety Evidence stage not applicable Certainty not assessed

    The same US label carries a boxed warning about the risk of induced arrhythmia in patients who start or restart the medicine. The warning also names the setting in which treatment is to begin; that instruction is not repeated here.

    Applies to Recipient not specified Patients starting or restarting Tikosyn, as described in a US label boxed warning

    Certainty method
    Not assessed
    Limitations
    This claim records the subject of the label's boxed warning only. The warning goes on to say what prescribers must do when treatment starts or restarts, and the label gives dosing instructions; those instructions are not repeated here. Other warnings, contraindications and interactions were not recorded. openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-18
    Next evidence check due
    Not scheduled
    Sources and citations (2)
    1. Supports openFDA drug label record for Tikosyn (dofetilide capsules), Pfizer Laboratories Div Pfizer Inc label: indications, mechanism, class, boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 02438044-d6a3-49e9-a1ac-3aad21ef2c8c (manufacturer Pfizer Laboratories Div Pfizer Inc, application NDA020931), returned on 2026-11-18. The label text is dated 2026-04-21 (effective_time). Other openFDA records of dofetilide labels from generic sponsors and repackagers exist and were not used.

      Locator
      results[0].boxed_warning[0], first sentence
      How it applies
      Label passage quoted in the research quote table (LB-11).
      Retrieved
      Source effective date
      2026-04-21
      Source state
      Current
      Version fingerprint
      97ab27af79e27cab8a79d0efa2c5d04e23b5628ffa5f726f662d99a2cf79bbb3
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Background openFDA drug label record for Tikosyn (dofetilide capsules), Pfizer Laboratories Div Pfizer Inc label: indications, mechanism, class, boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 02438044-d6a3-49e9-a1ac-3aad21ef2c8c (manufacturer Pfizer Laboratories Div Pfizer Inc, application NDA020931), returned on 2026-11-18. The label text is dated 2026-04-21 (effective_time). Other openFDA records of dofetilide labels from generic sponsors and repackagers exist and were not used.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20260421.
      Retrieved
      Source effective date
      2026-04-21
      Source state
      Current
      Version fingerprint
      97ab27af79e27cab8a79d0efa2c5d04e23b5628ffa5f726f662d99a2cf79bbb3
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.

Context Patients with atrial fibrillation or flutter, as described in the US label of Tikosyn

Recipient
Recipient not specified
Population
Patients described in the indications section of the label: patients with atrial fibrillation or flutter of more than one week's duration who have been converted to normal sinus rhythm, and patients in atrial fibrillation or flutter for whom conversion to normal sinus rhythm is sought. The passages read do not state an age range.
Care setting
Prescription medicine, as described in the US label
Geography
United States (label of the US Food and Drug Administration)
Life stage
Not stated in the label passages read
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (label statement)
Eligibility: 2 inclusion criteria; exclusion criteria not stated
Included
  • Patients with atrial fibrillation or flutter of more than one week's duration who have been converted to normal sinus rhythm
  • Patients with atrial fibrillation or flutter for whom conversion to normal sinus rhythm is sought
Excluded
None stated
  • Description Evidence stage not applicable Certainty not assessed

    The US label of Tikosyn (dofetilide capsules, Pfizer Laboratories Div Pfizer Inc, application NDA020931; the version dated 2026-04-21 in openFDA) lists the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation or flutter) in patients with atrial fibrillation or flutter of more than one week's duration who have been converted to normal sinus rhythm, and the conversion of atrial fibrillation and flutter to normal sinus rhythm. It states that the medicine has not been shown to be effective when the atrial fibrillation is paroxysmal.

    Applies to Recipient not specified Patients with atrial fibrillation or flutter, as described in the US label of Tikosyn

    Certainty method
    Not assessed
    Limitations
    This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label also says that, because the medicine can cause life-threatening ventricular arrhythmias, it should be reserved for patients whose atrial fibrillation or flutter is highly symptomatic; that is the label's statement, not the atlas's advice. Contraindications, other warnings, interactions, restricted-program requirements and dosing were not recorded. Generic dofetilide labels were not read. openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-18
    Next evidence check due
    Not scheduled
    Sources and citations (4)
    1. Supports openFDA drug label record for Tikosyn (dofetilide capsules), Pfizer Laboratories Div Pfizer Inc label: indications, mechanism, class, boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 02438044-d6a3-49e9-a1ac-3aad21ef2c8c (manufacturer Pfizer Laboratories Div Pfizer Inc, application NDA020931), returned on 2026-11-18. The label text is dated 2026-04-21 (effective_time). Other openFDA records of dofetilide labels from generic sponsors and repackagers exist and were not used.

      Locator
      results[0].description[0], first sentence
      How it applies
      Label passage quoted in the research quote table (LB-04).
      Retrieved
      Source effective date
      2026-04-21
      Source state
      Current
      Version fingerprint
      97ab27af79e27cab8a79d0efa2c5d04e23b5628ffa5f726f662d99a2cf79bbb3
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Supports openFDA drug label record for Tikosyn (dofetilide capsules), Pfizer Laboratories Div Pfizer Inc label: indications, mechanism, class, boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 02438044-d6a3-49e9-a1ac-3aad21ef2c8c (manufacturer Pfizer Laboratories Div Pfizer Inc, application NDA020931), returned on 2026-11-18. The label text is dated 2026-04-21 (effective_time). Other openFDA records of dofetilide labels from generic sponsors and repackagers exist and were not used.

      Locator
      results[0].indications_and_usage[0], maintenance of normal sinus rhythm
      How it applies
      Label passage quoted in the research quote table (LB-05, LB-06).
      Retrieved
      Source effective date
      2026-04-21
      Source state
      Current
      Version fingerprint
      97ab27af79e27cab8a79d0efa2c5d04e23b5628ffa5f726f662d99a2cf79bbb3
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    3. Supports openFDA drug label record for Tikosyn (dofetilide capsules), Pfizer Laboratories Div Pfizer Inc label: indications, mechanism, class, boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 02438044-d6a3-49e9-a1ac-3aad21ef2c8c (manufacturer Pfizer Laboratories Div Pfizer Inc, application NDA020931), returned on 2026-11-18. The label text is dated 2026-04-21 (effective_time). Other openFDA records of dofetilide labels from generic sponsors and repackagers exist and were not used.

      Locator
      results[0].indications_and_usage[0], conversion
      How it applies
      Label passage quoted in the research quote table (LB-07, LB-08).
      Retrieved
      Source effective date
      2026-04-21
      Source state
      Current
      Version fingerprint
      97ab27af79e27cab8a79d0efa2c5d04e23b5628ffa5f726f662d99a2cf79bbb3
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    4. Background openFDA drug label record for Tikosyn (dofetilide capsules), Pfizer Laboratories Div Pfizer Inc label: indications, mechanism, class, boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 02438044-d6a3-49e9-a1ac-3aad21ef2c8c (manufacturer Pfizer Laboratories Div Pfizer Inc, application NDA020931), returned on 2026-11-18. The label text is dated 2026-04-21 (effective_time). Other openFDA records of dofetilide labels from generic sponsors and repackagers exist and were not used.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20260421.
      Retrieved
      Source effective date
      2026-04-21
      Source state
      Current
      Version fingerprint
      97ab27af79e27cab8a79d0efa2c5d04e23b5628ffa5f726f662d99a2cf79bbb3
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.

Clinical links

Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.

Record details

Record id
cardio:dofetilide
Content hash
717bd69ce8d1e9aa56bb79bc9b5545c4a66467ef33fa76fabceed15d4abd5ebf